系统性红斑狼疮患者抗疟药依从性与2型糖尿病风险的人群研究
基于加拿大不列颠哥伦比亚省行政健康数据库的回顾性纵向队列研究,纳入1498例新发SLE且新开始抗疟药治疗的患者(90.8%女性),中位随访4.62年。结果显示,与停药者相比,依从者(PDC≥0.90)发生2型糖尿病的多变量风险比为0.61(95%CI 0.40-0.93),非依从者为0.78(95%CI 0.50-1.22)。结论提示坚持抗疟药治疗可能降低2型糖尿病风险。
要点
- 抗疟药高依从性(PDC≥0.90)与2型糖尿病风险降低相关(HR 0.61)。
- 非依从者风险降低无统计学显著性(HR 0.78,95%CI 0.50-1.22)。
- 研究支持通过坚持抗疟药治疗以获得其潜在代谢获益。
核心结论
- 在SLE患者中,对抗疟药高度依从与2型糖尿病风险降低独立相关,支持坚持用药以获取治疗获益。
研究设计与样本
- 加拿大不列颠哥伦比亚省行政健康数据库的回顾性纵向队列研究,纳入1498例新发SLE且新开始抗疟药治疗的患者,90.8%为女性,中位随访4.62年。
主要发现
- 随访期间共记录140例新发2型糖尿病。
- 与停药者相比,依从者(PDC≥0.90)发生2型糖尿病的多变量风险比为0.61(95%CI 0.40-0.93)。
- 非依从者(0<PDC<0.90)的风险比为0.78(95%CI 0.50-1.22)。
关键数值与推荐
- 抗疟药疗程定义:两次续药间隔超过90天即视为新疗程,并计算每个疗程的覆盖天数比例(PDC)。
- 用药状态分类:依从(PDC≥0.90)、非依从(0<PDC<0.90)、停药(无药物)。
- 2型糖尿病结局基于门诊或住院就诊或使用降糖药物判定。
临床怎么用
- 在SLE管理中应重视抗疟药依从性评估与干预,以潜在降低2型糖尿病风险。
- 对计划或正在使用抗疟药的患者,可结合用药依从性进行代谢风险分层管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association between adherence to antimalarials and type 2 diabetes mellitus (DM) in patients with systemic lupus erythematosus (SLE). METHODS: Using administrative health databases in British Columbia, Canada, we conducted a retrospective, longitudinal cohort study of patients with incident SLE and incident antimalarial use. We established antimalarial drug courses by defining a new course when a 90-day gap is exceeded between refills and we calculated proportion of days covered (PDC) for each course. We categorized medication taking as: 1) adherent (PDC ≥0.90), 2) nonadherent (0 < PDC < 0.90), and 3) discontinuer (no drug). Type 2 DM outcomes were based on outpatient or inpatient visits, or antidiabetic medication use. We used multivariable Cox proportional hazards models with time-dependent variables. RESULTS: Over a median of 4.62 years of follow-up in our incident cohort of 1,498 patients with SLE (90.8% women), we recorded 140 incident cases of type 2 DM. Multivariable hazard ratios were 0.61 (95% confidence interval [95% CI] 0.40-0.93) for adherent and 0.78 (95% CI 0.50-1.22) for nonadherent, respectively, as compared to discontinuers. CONCLUSION: Our findings of a protective effect of adherence to antimalarials in preventing type 2 DM provides further support for the importance of adherence to antimalarials to obtain the benefits of therapy.
引用
- Salmasi S, Sayre EC, Antonio Aviña-Zubieta J, et al. Adherence to Antimalarial Therapy and Risk of Type 2 Diabetes Mellitus Among Patients With Systemic Lupus Erythematosus: A Population-Based Study. Arthritis Care Res (Hoboken). 2021. PMID: 31961497. doi:10.1002/acr.24147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。